Table4_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table2_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table8_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table5_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table3_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table7_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Table1_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.DOCX by J. Riera-Arnau (20431328)

“…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”

Data Sheet 1_Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greate... by Ayman Alhejazi (21092054)

“…Background<p>Multiple myeloma (MM) is a plasma cell malignancy with significant unmet medical needs, particularly in the treatment of relapsed and refractory disease. …”

Data Sheet 1_Artificial intelligence-assisted delineation for postoperative radiotherapy in patients with lung cancer: a prospective, multi-center, cohort study.docx by Ziming Han (19926057)

“…In addition to better contouring accuracy, the AI-assisted delineation significantly decreased the consuming time and improved the efficiency.…”

Figure 5 from Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma by Zelei Yang (18491142)

“…The individual points for each cell line in the individual graph for each treatment represent the average of three experiments, and error bars represent standard error of the mean. An ordinary one-way ANOVA with Šídák’s multiple comparisons test was performed to assess the significance of the difference between either the 4 hour or the 24 hour timepoint and the 45 minute timepoint for each cell line within each treatment. …”

Figure 2 from Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in <i>EGFR</i>- and <i>KRAS</i>-Mutant Lung Cancer by Xiaoxiao Sun (20589448)

“…<p>PRMT1 knockdown decreases persistence in STAT1-high <i>EGFR</i>^<i>mut</i> and <i>KRAS</i>^<i>G12C</i> lung cancer cell lines. …”

Data Sheet 1_Artificial intelligence–enhanced mapping of the international classification of functioning, disability and health via a mobile app: a randomized controlled trial.zip... by Zhandos Kurban (21985553)

“…Mean SUS score among physicians was 86.8, indicating excellent usability and acceptability.…”

Table 2_Impact of chemoradiotherapy for first primary lung cancer on the prognosis and re-chemoradiotherapy sensitivity of second primary lung cancer.docx by Zhe Chen (196097)

“…We employed the Fine-Gray competitive risk model, Cox proportional hazards model, and restricted mean survival time analysis to assess the effects of FPLC radiotherapy and chemotherapy on SPLC risk and survival differences.…”

Data Sheet 1_Impact of chemoradiotherapy for first primary lung cancer on the prognosis and re-chemoradiotherapy sensitivity of second primary lung cancer.xlsx by Zhe Chen (196097)

“…We employed the Fine-Gray competitive risk model, Cox proportional hazards model, and restricted mean survival time analysis to assess the effects of FPLC radiotherapy and chemotherapy on SPLC risk and survival differences.…”

Table 3_Impact of chemoradiotherapy for first primary lung cancer on the prognosis and re-chemoradiotherapy sensitivity of second primary lung cancer.docx by Zhe Chen (196097)

“…We employed the Fine-Gray competitive risk model, Cox proportional hazards model, and restricted mean survival time analysis to assess the effects of FPLC radiotherapy and chemotherapy on SPLC risk and survival differences.…”

Table 1_Impact of chemoradiotherapy for first primary lung cancer on the prognosis and re-chemoradiotherapy sensitivity of second primary lung cancer.docx by Zhe Chen (196097)

“…We employed the Fine-Gray competitive risk model, Cox proportional hazards model, and restricted mean survival time analysis to assess the effects of FPLC radiotherapy and chemotherapy on SPLC risk and survival differences.…”

Table 1_The role of serum albumin and albumin-related nutritional indices in predicting post-stroke cognitive impairment: a systematic review and meta-analysis.docx by Yan-qiu Wang (20565725)

“…We systematically searched six databases with a time frame from the date of database establishment to March 29, 2025. …”

Table 1_Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine.docx by Zhifei Chen (1740625)

“…We evaluated humoral immune responses and their longevity by measuring the geometric mean titers (GMTs) of neutralizing antibodies against the SARS-CoV-2 virus at various time points post-boost. …”

Hemostatic changes following COVID-19 vaccination: Do they promote a pro-thrombotic state? by Tarinee Rungjirajittranon (6268034)

“…BNT162b2 group platelet counts increased significantly on day 7 (<i>p</i> = .010). TGA parameters in the ChAdOx1-S group decreased significantly in ETP levels (<i>p</i> = .007) and peak concentrations (<i>p</i> = .041) over time while those of the BNT162b2 group were stable (median ETP levels and peak concentrations; <i>p</i> > .05). …”

SEAwise Report on improved predictive models of recruitment under different habitat scenarios and incorporating experimental results by Paco Melià (162862)

“…Recruitment of Western Baltic cod and herring showed decreasing reproductive potential as temperature increased.…”